ImmunisBio Unveils AI-Based Automated Cell Culture System for the First Time

ImmunisBio, an immunocyte therapy research company, announced on September 22 that it will participate in the "2025 Korea Life Science Week," South Korea's leading life science business platform, to be held at COEX in Seoul from September 30 to October 1. The company will unveil its innovative "AI-based Automated Cell Culture System" for the first time, which is expected to revolutionize the paradigm of cell therapy product manufacturing.

This system is anticipated to dramatically improve the production efficiency and quality consistency-two core challenges in the commercialization of cell therapies-thereby accelerating the popularization of next-generation cancer treatments.

The AI-based Automated Cell Culture System is designed to address chronic issues in the cell therapy manufacturing process. Traditional manual methods have relied heavily on skilled researchers and have suffered from risks of contamination and variability among operators, resulting in inconsistent product quality. High production costs and limited scalability have also been major barriers to patient access to these treatments.

ImmunisBio’s automated system standardizes the entire process, including media addition, cell proliferation monitoring, and subculturing. Using AI-powered image analysis technology, it optimally manages cell growth in real time. This approach maximizes productivity and reduces labor costs while ensuring that high-quality cell therapy products can be reliably supplied from every production unit.

During the event, ImmunisBio will exhibit the actual system and conduct live demonstrations. Visitors will have the opportunity to experience the future of cell therapy manufacturing by witnessing firsthand how AI manages cell quality and intelligently controls the production process.

On the first day of the event, September 30 at 2 p.m., CEO Kang Junghwa will participate as a panelist in the "International Forum on Advanced Regenerative Medicine Development Strategies." Kang will discuss the importance of a regulatory environment that keeps pace with technological advancements, focusing on the need to expand the scope of advanced regenerative medicine and adjust risk levels. Policy directions will be presented. On the same day at 10:20 a.m., a professional seminar titled "Redefining the Paradigm of Cell Therapy Development" will be held in Seminar Room B. The seminar will provide in-depth insights into how automation technology is transforming the entire cycle of cell therapy, from research and development (R&D) to commercial production.

Kang Junghwa, CEO of ImmunisBio, stated, "The AI-based Automated Cell Culture System is more than just an engineering achievement; it is a core technology that fulfills our promise to provide personalized cell therapies to all patients." She added, "By standardizing and automating the production process, we will usher in a new era of safer, more effective, and reasonably priced therapies. We will continue to strengthen our vision to lead the paradigm in the field of solid tumor treatment."